Equities researchers at Cantor Fitzgerald began coverage on shares of Anteris Technologies Global (NASDAQ:AVR – Get Free Report) in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage set an “overweight” rating and a $9.00 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 60.43% from the stock’s previous close.
Separately, Barclays initiated coverage on shares of Anteris Technologies Global in a research note on Tuesday. They issued an “overweight” rating and a $22.00 target price on the stock.
Check Out Our Latest Research Report on AVR
Anteris Technologies Global Stock Up 0.4 %
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
See Also
- Five stocks we like better than Anteris Technologies Global
- Top Biotech Stocks: Exploring Innovation Opportunities
- Will Berkshire Hathaway Continue to Dominate in 2025?
- Top Stocks Investing in 5G Technology
- 2 Agriculture Stocks To Benefit From a Trump Presidency in 2025
- How to Invest in Small Cap StocksÂ
- Uber’s Future: Analysts Forecast a 40% Stock Surge in 2025
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.